Clearstead Advisors, LLC Xenon Pharmaceuticals Inc. Transaction History
Clearstead Advisors, LLC
- $7.4 Billion
- Q3 2025
A detailed history of Clearstead Advisors, LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 386 shares of XENE stock, worth $15,733. This represents 0.0% of its overall portfolio holdings.
Number of Shares
386
Previous 347
11.24%
Holding current value
$15,733
Previous $10,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding XENE
# of Institutions
240Shares Held
74MCall Options Held
235KPut Options Held
271K-
Avoro Capital Advisors LLC New York, NY5.4MShares$220 Million2.96% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.17MShares$170 Million1.42% of portfolio
-
Janus Henderson Group PLC London, X03.94MShares$161 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.61MShares$147 Million0.03% of portfolio
-
Braidwell LP Stamford, CT3.61MShares$147 Million8.35% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.54B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...